

Sl. No.	Particulars	AUDITED		AUDITED	
		3 Months ended 31.12.2011	3 Months ended 30.09.2011	3 Months ended 31.12.2010	12 Months ended 31.12.2011
1	(a) Net Sales / Income from Operations	19,545.13	19,602.10	12,793.35	71,435.54
	(b) Other Operating Income	247.17	96.26	126.53	448.35
	<b>Total Income</b>	<b>19,792.30</b>	<b>19,698.36</b>	<b>12,919.88</b>	<b>72,083.89</b>
2	Expenditure	131.04	(225.41)	(158.26)	661.87
	(a) (Increase) / decrease in stock in trade and work in progress	8,356.45	9,872.00	6,210.98	30,765.59
	(b) Consumption of materials	2,226.40	3,321.60	1,375.13	11,739.35
	(c) Purchase of traded goods	1,490.23	1,725.07	1,511.59	6,297.71
	(d) Employee cost	570.49	400.99	469.19	1,761.49
	(e) Depreciation	3,217.41	3,529.11	2,815.06	10,613.30
	(f) Other Expenditure	15,992.02	18,523.36	12,223.69	61,839.31
	<b>Total Expenditure</b>	<b>3,800.28</b>	<b>1,075.00</b>	<b>696.19</b>	<b>10,244.58</b>
3	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>4,540.80</b>	<b>1,075.00</b>	<b>4,551.48</b>	<b>6,544.20</b>
4	Other Income	8,341.08	1,075.00	5,247.67	14,785.38
5	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	<b>1,746.83</b>	<b>2,083.81</b>	<b>1,663.04</b>	<b>11,095.68</b>
6	Interest (net)	6,594.25	(1,008.81)	3,584.63	7,337.42
7	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>9,425.49</b>	<b>(6,104.60)</b>	<b>561.91</b>	<b>3,702.10</b>
8	<b>Exceptional Items:</b>				
	- Exchange Fluctuation (loss) / gain (Net)	-	-	482.92	-
	- Exchange (loss) / gain on restatement of Hedged Investments (Refer Note 10 below)	-	-	881.98	944.02
	- Profit on sale of Investment	36.78	-	593.07	1,888.55
	- Changes in fair value of Options embedded in FCCBs (loss) / gain	-	93.95	1,838.75	-
	- Provision for diminution in value of Investment reversed	-	-	7,943.26	12,617.15
9	<b>Profit / (Loss) from Ordinary Activities before tax (7+ 8)</b>	<b>16,056.52</b>	<b>(7,019.46)</b>	<b>13,000.11</b>	<b>19,225.00</b>
10	Tax Expense / (Credit)	1,580.00	(500.00)	-	(1,100.00)
	- Current	(1,100.00)	-	-	-
	- MAT Credit entitlement	15,576.52	(6,519.46)	6,643.25	11,792.15
11	<b>Net Profit / (Loss) from Ordinary activities after tax (9-10)</b>	<b>15,576.52</b>	<b>(6,519.46)</b>	<b>6,643.25</b>	<b>7,356.08</b>
12	Extraordinary Item	-	-	-	-
13	<b>Net Profit / (Loss) for the period / year (11-12)</b>	<b>15,576.52</b>	<b>(6,519.46)</b>	<b>6,643.25</b>	<b>7,356.08</b>

*Am*

14	Paid-up Equity Share Capital (Face value of Rs.10/-each)	5,838.02	5,837.42	5,774.47	5,838.02	5,774.47
15	Reserves excluding revaluation reserves					134,627.49
16	<b>Earnings per Share (EPS) :</b>					
	Basic & Diluted EPS after Extraordinary Items for the year (Rs. per share)					
	(a) Basic EPS	26.68	(11.21)	11.51	20.30	15.69
	(b) Diluted EPS	26.57	(11.21)	8.67	20.13	11.98
17	<b>Aggregate of Public shareholding :</b>					
	(a) Number of shares	41,785,913	41,779,913	41,401,298	41,785,913	41,401,298
	(b) Percentage of shareholding	71.58%	71.57%	71.70%	71.58%	71.70%
18	<b>Promoters and Promoter group shareholding :</b>					
	(a) Pledged / Encumbered					
	- Number of shares	11,559,985	10,328,285	8,000,000	11,559,985	8,000,000
	- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	69.66%	62.24%	48.99%	69.66%	48.99%
	- Percentage of shareholding (as a % of the total share capital of the Company)	19.80%	17.69%	13.85%	19.80%	13.85%
	(b) Non Pledged / Non Encumbered					
	- Number of shares	5,034,273	6,265,973	8,343,373	5,034,273	8,343,373
	- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	30.34%	37.76%	51.05%	30.34%	51.05%
	- Percentage of shareholding (as a % of the total share capital of the Company)	8.62%	10.74%	14.45%	8.62%	14.45%

*Am*



Regd. Office: No. 201 Devavreda, Sector 17, Vashi, Navi Mumbai 400 703.  
 Corp. Office: "Strides House", Bilekchalli, Bommerghatta Road, Bangalore-560 076.

**AUDITED FINANCIAL RESULTS**  
**FOR THE YEAR ENDED DECEMBER 31, 2011**

**STATEMENT OF ASSETS AND LIABILITIES AS AT -**

Particulars	AUDITED	
	12 Months ended 31.12.2011	12 Months ended 31.12.2010
	(1)	(2)
<b>SOURCES OF FUNDS</b>		
A. Share Capital	5,838,02	5,774.47
B. Employees stock options outstanding account	275,90	208,57
C. Reserves and surplus	129,807.20	134,627.49
D. Loan funds	143,980.09	124,306.85
<b>Total</b>	<b>279,901.21</b>	<b>264,917.38</b>
<b>APPLICATION OF FUNDS</b>		
<b>A. Fixed assets (net)</b>	33,189.34	34,904.35
<b>B. Investments</b>	78,681.82	86,452.00
<b>C. Current assets</b>		
- Inventories	13,031.92	12,930.76
- Sundry Debtors	26,428.34	15,973.02
- Unbilled Debtors	3,056.19	1,452.75
- Cash and bank balances	8,146.17	8,101.56
- Loans and advances	170,463.15	142,102.31
<b>D. Current Liabilities &amp; Provisions</b>		
- Current liabilities	(31,599.22)	(22,090.86)
- Provisions	(21,496.50)	(14,908.51)
<b>Net Current Assets (C-D)</b>	<b>148,030.05</b>	<b>143,561.03</b>
<b>Total</b>	<b>279,901.21</b>	<b>264,917.38</b>

Rs. in Lakhs

*Handwritten signature*



Regd. Office: No. 201 Devarajra, Sector 17, Vashi, Navi Mumbai 400 703.  
 Corp. Office: "Strides House", Bilekahalli, Banerghatta Road, Bangalore-560 076.  
**AUDITED FINANCIAL RESULTS**  
**FOR THE YEAR ENDED DECEMBER 31, 2011**

**Notes:**

- The above audited results of the Company has been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on February 27, 2012.
- The Statutory Auditors have carried out audit of the above standalone results.
- The previous period's figures have been regrouped/reclassified whenever necessary to conform to current period's classification.
- Figures for the quarter ended December 31, 2011 and December 31, 2010 are the balancing figures between (a) the audited figures of the respective financial year end and (b) the published year to date figures up to the third quarter of the respective financial years which have been reclassified as per the classification followed in the respective year ends.
- Consequent to the approval of Scheme of Arrangement during the year ending December 31, 2009 by the Hon'ble High Courts of Judicature (the Scheme), the Company has utilised the Reserve for Business Restructure (BRR) as mentioned below. In the year 2009, as per the Scheme, investments in a subsidiary had been fair valued and the resultant surplus over the previously carried book values, amounting to Rs. 58,562 Lakhs had been credited to BRR.

Rs. in Lakhs

Particulars	3 Months ended 31.12.2011 (Refer Note 4 above)	3 Months ended 30.09.2011	3 Months ended 31.12.2010 (Refer Note 4 above)	12 Months ended 31.12.2011	12 Months ended 31.12.2010
<b>Utilisation of BRR :</b>					
- Employee compensation	32.14	17.61	(128.43)	316.16	387.08
- <b>Impairment of Fixed Assets</b>	265.96	-	-	265.96	-
Current Assets	-	-	-	355.47	-
- Depreciation and Amortisation	428.62	428.61	444.31	1,700.49	1,696.24
- Other expenses	574.50	-	874.89	685.41	911.23
- Interest on Fixed Loans	1,039.05	450.00	-	1,489.05	-
Reclassification of assets written off earlier	-	-	(2,064.90)	(4.64)	(2,523.06)
Impact if the Company followed the Accounting Standards instead of the accounting treatment provided in the Scheme :-					
<b>Net Profit for the year ended December 31, 2011 would have been decreased by :</b>	<b>2,340.27</b>	<b>896.22</b>	<b>(874.13)</b>	<b>4,807.90</b>	<b>469.49</b>
<b>Earnings / (Loss) per share (EPS) (Face value of Rs.10/-each) (Rs.)</b>					
Basic	22.67	(12.75)	13.02	12.03	14.69
Diluted	22.57	(12.75)	10.00	11.92	11.18

*pm*




Regd. Office: No. 201 Devarajaya Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.  
AUDITED FINANCIAL RESULTS

**FOR THE YEAR ENDED DECEMBER 31, 2011**

- 6 During the year, 410,500, 75,000 & 150,000 equity shares were allotted by the Company on exercising equal number of options under Strides Arcolab ESOP 2008, ESOP 2008 (Directors) & 2006 Schemes respectively. Further, 189,500, 500,000 options were granted to eligible employees of the Company under the ESOP 2008 Scheme and ESOP 2006 Schemes respectively. During the year, the ESOP scheme titled "Strides Arcolab ESOP 2011" (ESOP 2011) was approved by the shareholders on May 30, 2011. 1,500,000 options are covered under the scheme for 1,500,000 shares. No options were granted under this scheme in the current year.
- 7 During the current year, as part of corporate readjustment, the following changes were done to subsidiaries within the Strides Group:
- a) Starsmore Limited has been renamed as Agila Specialties Limited
  - b) Linkace Limited has been renamed as Strides Pharma Limited
  - c) Strides Specialties Cyprus Limited has been renamed as Strides Pharma International Limited
  - d) Strides Specialties (Holdings) Cyprus Limited has been transferred from Strides Specialties (Holdings) Limited to Agila Specialties Limited.
  - e) Onco Laboratories Limited has been transferred from Agila Specialties Limited to Strides Specialties (Holdings) Cyprus Limited
  - f) Onco Therapies Limited has been transferred from Strides Arcolab Limited to Agila Specialties Private Limited
  - g) Strides Arcolab Polska Sp. Z.o.o. has been transferred from Strides Pharma Limited to Agila Specialties Limited
  - h) Farma Plus AS has been transferred from Plus Farma EHF to Agila Specialties Limited
  - i) Strides Pharma International Limited has been transferred from Strides Specialties (Holdings) Cyprus Limited to Strides Arcolab Limited
  - j) Strides Vital Nigeria Limited has been transferred from Strides Africa BVI to Strides Pharma Limited and then to Strides Pharma (Cyprus) Limited
- 8 During the year, the Group completed a Scheme of Implementation to acquire a majority of the minority shares of Ascent Pharmaceutical Limited (APH). Subsequent to current year end, investment in APH has been sold for a consideration of AUD 3,750 Lakhs (INR 200,000 Lakhs).
- 9 On completion of certain legal formalities, the Company obtained control over EPHOS - 106 Produtos Hospitalares Ltda. ME, Brazil and Agila Especialidades Farmaceuticas Ltda. Brazil, through its step down subsidiaries.
- 10 Exchange fluctuation gain/loss (net) includes under Exceptional Items comprises the unrealized gains/losses arising out of the restatement of FCCBs, borrowings in foreign currency, intra group loans given and certain foreign currency denominated monetary items.
- 11 The Company had early adopted Accounting Standard (AS) 30 'Financial Instruments: Recognition and Measurement' and in the spirit of full adoption, the Company had also adopted the limited revision to other notified AS. In accordance with these provisions, certain investments which were designated in a fair value hedge relationship were restated at the period end rates. Pursuant to the notification dated February 11, 2011 issued by the Institute of Chartered Accountants of India, which clarified that the provisions of AS 30 would need to be applied only to the extent they do not contravene the other mandatory accounting standards, during the quarter ended December 31, 2010, the Company reversed certain restatements done in prior quarters that were not consistent with the mandatory Accounting Standards. The exchange gain / (loss) recognised in the quarter ended December 31, 2010 on account of such change was Rs. 482.92 Lakhs.
- 12 The Company's operations fall within a single business segment viz. "Pharmaceutical Products" and as such there is no reportable segment information as per Accounting Standard 17 issued under the relevant provision of the Companies Act, 1956.
- 13 Investor grievances received and disposed of during the quarter ended December 31, 2011 :  
a) Pending complaints at the beginning of the quarter - Nil b) No. of Complaints received - 16  
c) Complaints disposed - 16 d) Complaints unresolved - Nil
- 14 The Board of Directors have recommended an equity dividend of Rs.2.00 per share for the year ended December 31, 2011.

Bangalore, February 27, 2012

  
**For and on behalf of the Board**  
Arun Kumar  
Vice Chairman & Managing Director